DelveInsight’s “Retinitis Pigmentosa Pipeline Insight 2023” report provides comprehensive global Retinitis Pigmentosa coverage of available, marketed, and Retinitis Pigmentosa Pipeline therapies in various stages of Retinitis Pigmentosa clinical trials development, major pharmaceutical Retinitis Pigmentosa Companies are working to advance the Retinitis Pigmentosa pipeline space and future growth potential of the Retinitis Pigmentosa pipeline domain.
For Retinitis Pigmentosa Emerging Drugs, the Retinitis Pigmentosa Pipeline analysis report provides a 360° view of the Retinitis Pigmentosa pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Retinitis Pigmentosa pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Retinitis Pigmentosa Pipeline Report
- Over 45+ Retinitis Pigmentosa companies are evaluating 45+ Retinitis Pigmentosa pipeline therapies in various stages of development, and their anticipated acceptance in the Retinitis Pigmentosa market would significantly increase market revenue.
- The leading Retinitis Pigmentosa Companies includes Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
- Promising Retinitis Pigmentosa Pipeline Therapies includes AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, and others.
- The Retinitis Pigmentosa Companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The Retinitis Pigmentosa pipeline therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.
- In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.
Request a sample and discover the recent breakthroughs happening in Retinitis Pigmentosa Pipeline Landscape @ Retinitis Pigmentosa Pipeline Outlook Report
Retinitis Pigmentosa Overview
Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.
Retinitis Pigmentosa Emerging Drugs Profile
- BIIB-112: Biogen
BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.
- QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.
Find out more about the Retinitis Pigmentosa Diagnosis and Treatment of patients @ Retinitis Pigmentosa Ongoing Clinical Trials Analysis
Retinitis Pigmentosa Companies and Pipeline Therapies
- Biogen: AAV2/5-RPGR
- Neurotech: CPK850
- Ionis Pharmaceuticals: Ophthalmic examinations
- Nacuity Pharmaceuticals: Mobility Test
- Allegro Ophthalmics: NT-501
- ID Pharma: RST-001
Retinitis Pigmentosa Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Discover more about the list of Retinitis Pigmentosa FDA-approved drugs for Retinitis Pigmentosa @ Retinitis Pigmentosa Treatment Landscape
Scope of the Retinitis Pigmentosa Pipeline Report
- Coverage- Global
- Retinitis Pigmentosa Companies- Biogen (NYSE: BIIB), Neurotech International Inc (NYSE: NTI), Ionis Pharmaceuticals (NYSE: IONS), Novartis Pharmaceuticals (NYSE: NVS), Nacuity Pharmaceuticals, ReNeuron Group Inc (NYSE: RNUGF), ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine (NYSE: EDIT), OiDE OptoEye, and others
- Retinitis Pigmentosa Pipeline Therapies- AAV2/5-RPGR, CPK850, Ophthalmic examinations, Mobility Test, NT-501, RST-001, and others.
- Retinitis Pigmentosa Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for Retinitis Pigmentosa Emerging Therapies and Ongoing Clinical Trials; visit @ Retinitis Pigmentosa Emerging Therapies and Companies
Table of Content
- Introduction
- Retinitis Pigmentosa Executive Summary
- Retinitis Pigmentosa: Overview
- Retinitis Pigmentosa Pipeline Therapeutics
- Retinitis Pigmentosa Therapeutic Assessment
- Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Retinitis Pigmentosa Collaboration Deals
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BIIB-112: Biogen
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- N-acetylcysteine-amide: Nacuity Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SPVN 06: SparingVision
- Drug profiles in the detailed report…..
- Inactive Products
- Retinitis Pigmentosa Key Companies
- Retinitis Pigmentosa Key Products
- Retinitis Pigmentosa- Unmet Needs
- Retinitis Pigmentosa- Market Drivers and Barriers
- Retinitis Pigmentosa- Future Perspectives and Conclusion
- Retinitis Pigmentosa Analyst Views
- Retinitis Pigmentosa Key Companies
- Appendix
For further information on the Retinitis Pigmentosa Pipeline therapeutics, reach out @ Retinitis Pigmentosa Market Drivers and Barriers
Latest Pharmaceuticals Market Research Reports in 2023
Trichotillomania market | Myopia progression market | Temporomandibular disorders market | Immune thrombocytopenia market | Spondylolisthesis market | Supraventricular tachycardia market | Tay-sachs disease market | Varicella zoster HHV 3 infections market | X-linked retinitis Pigmentosa market | Progressive Supranuclear palsy market report | Sly syndrome Market | Erosive hand osteoarthritis market |Coronary stents pipeline | Bone Anchored Hearing Systems Market | Adrenocortical Carcinoma Market | Hip Replacement Devices Market | Dermal Erythema Market | Acoustic Neuroma Market | Meningioma Market | Bronchial Spasm Market | Age Related Vision Dysfunction Market
Published Healthcare Blogs by DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com